U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07913919) titled 'Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study' on Oct. 27.
Brief Summary: People with systemic lupus erythematous (SLE) have an increased risk of premature atherosclerotic cardiovascular disease, which is believed to be caused by arterial inflammation. The aim of this study is to investigate the effects an interferon-targeting drug (anifrolumab) used for the treatment of active SLE on arterial inflammation. Arterial inflammation will be measured at baseline and after 4 months of treatment using Positron Emission Tomography (PET)/ Magnetic Resonance Imaging (MRI) with a radio-labelled tracer (68G...